Drug Use-Results Survey of Betanis Tablets in Japan
Launched by ASTELLAS PHARMA INC · Aug 6, 2013
Trial Information
Current as of June 21, 2025
Completed
Keywords
ClinConnect Summary
This survey aims to determine the following information and the need for conducting specified drug use-results surveys and post-marketing clinical studies in patients using Betanis (generic name: mirabegron):
1. The occurrence of adverse drug reactions in clinical settings.
2. Factors potentially impacting safety, effectiveness, and other aspects.
Items of Particular Interest:
* Safety and effectiveness in patients with hepatic impairment and patients with renal impairment.
* Safety and effectiveness when mirabegron is used concomitantly with other drugs (α1 blockers, anticholinergic age...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who received mirabegron for the first time for the treatment of urinary urgency, daytime frequency, and urgency incontinence associated with overactive bladder.
About Astellas Pharma Inc
Astellas Pharma Inc. is a global pharmaceutical company dedicated to improving the health of patients through innovative research and development. With a strong focus on urology, oncology, immunology, and neuroscience, Astellas is committed to advancing medical science and delivering transformative therapies. The company operates with a patient-centric approach, striving to address unmet medical needs while adhering to the highest standards of ethics and compliance in clinical trials. Astellas leverages cutting-edge technology and collaborates with healthcare professionals and institutions worldwide to bring forward new treatment options that enhance the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hokkaido, , Japan
Chubu, , Japan
Chugoku, , Japan
Shikoku, , Japan
Kansai, , Japan
Kyushu, , Japan
Touhoku, , Japan
Kantou, , Japan
Patients applied
Trial Officials
Central Contact
Study Chair
Astellas Pharma Inc
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials